Aug 15, 2025, 17:30 ET Wegovy (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity 1 The accelerated approval is based on Part 1 of the ESSENCE trial, in which Wegovy demonstrated a statistically significant improvement in liver fibrosis (liver scarring) with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo 1,2 Wegovy is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight, and for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off 1 PLAINSBORO, N.J., Aug
Structure, mechanism and regulation of peroxiredoxins
For now, the best path forward is to stick with therapies backed by solid, long-term data, using GLP-1 agonists as a potential supplement for managing metabolic issues
According to NICE guideline NG198 on acne management, first-line options include fixed-combination topical treatments such as adapalene with benzoyl peroxide or benzoyl peroxide with clindamycin
